Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma
NORTHWEST BIOTHRPUTCS INC (NWBO)
US:NASDAQ Investor Relations:
nwbio.com/investors-media
Company Research
Source: PR Newswire
Both Median Survival and "Long Tail" of Extended Survival Were Increased In Both Newly Diagnosed and Recurrent GlioblastomaResults Featured In JAMA Oncology Peer Reviewed PublicationBETHESDA, Md., Nov. 17, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported that in its Phase III clinical trial both median survival and the "long tail" of extended survival were increased in both newly diagnosed and recurrent glioblastoma brain cancer patients treated with DCVax®-L. The trial has met both the primary and the secondary endpoint under the Statistical Analysis Plan for the trial.The trial results were reported today in a featured publication co-authored by more than 70 physicians from leading institutions across the U.S., Canada, U.K. and Germany, in the peer reviewed cancer journal JAMA Oncology, entitled "Association of Autologous Tumor Lysate-Loaded Dendrit
Show less
Read more
Impact Snapshot
Event Time:
NWBO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NWBO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NWBO alerts
High impacting NORTHWEST BIOTHRPUTCS INC news events
Weekly update
A roundup of the hottest topics
NWBO
News
- Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of DirectorsPR Newswire
- Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification [Yahoo! Finance]Yahoo! Finance
- Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory CertificationPR Newswire
- Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory CertificationPR Newswire
NWBO
Sec Filings
- 3/22/24 - Form 8-K
- 3/14/24 - Form 8-K
- 3/5/24 - Form 10-K
- NWBO's page on the SEC website